VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
OMER
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
OMEROmeros Corporation
$17.49$1.2B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksOMERCash Flow

Omeros Corporation (OMER) Cash Flow Statement

19Y historyFree accessUpdated daily

While Q2 2026 generated positive free cash flow of $4.1 million, this follows a historical pattern of severe cash burn, and the operating cash flow conversion of 31% relative to net income suggests limited cash generation from the new revenue stream.

Income StatementBalance SheetCash FlowRatios

OMER Cash Flow Statement

Annual statement

OMER Cash Flow Statement

Omeros Corporation (OMER) cash flow statement — 19-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07
Cash from Operations-68.67M-116.09M-148.8M74.73M-86.48M-109.72M-100.09M-60.07M-103.74M-36.23M-51.5M-65.21M-58.04M-29.7M-34.55M-25.67M-14.5M-19.03M-19.67M-14.31M
Operating CF Margin %--------53.73%-347.32%-55.88%-123.76%-482.71%-10768.83%-1855.94%-573.75%-567.37%-688.93%-1317.66%-1681.45%-744.36%
Operating CF Growth %183.33%21.98%-299.13%186.41%21.18%-9.63%-66.61%42.09%-186.35%29.66%21.02%-12.34%-95.47%14.05%-34.61%-77%23.78%3.28%-37.44%-
Net Income124.83M-3.35M-156.81M-117.81M-182.03M-191.55M-138.06M-84.49M-126.76M-53.48M-66.75M-75.1M-73.67M-39.8M-38.44M-28.55M-29.25M-21.09M-23.83M-23.09M
Depreciation & Amortization907K964K950K920K952K1.39M1.62M1.79M962K551K300K209K326K302K320K435K472K451K434K375K
Stock-Based Compensation5.29M8.19M10.49M11.65M0014.93M13.79M11.71M12.69M13.58M9.58M8.92M6.25M4.28M1.93M2.18M1.49M2.31M6.06M
Deferred Taxes000000-12.01M0-12.93M05.59M1.31M854K41K511K28.55M329K34K294K-145K
Other Non-Cash Items-216.82M-155.62M-33.17M-67.45M213.56M94.54M25.86M9.23M18.98M4.19M1.98M1.04M738K502K354K-28.19M174K-595K2M503K
Working Capital Changes21.93M33.72M29.74M247.42M-118.97M-14.11M7.58M-394K4.29M-172K-6.21M-2.26M4.79M3M-1.57M164K11.6M678K-892K1.99M
Change in Receivables25.94M30.45M40.01M245.72M-175.07M-34.31M31.34M-12.37M-6.17M-5.11M-5.52M-6.13M-13K1.55K-1.06K00000
Change in Inventory-842K00000-208K-1.06M355K685K-656K96K-568K0000000
Change in Payables1.24M000-10.66M14.64M-19.74M13.28M10.54M9.52M-319K4.2M5.46M-1.17M957K1.46M1.46M-140K00
Cash from Investing136.82M164.52M82.22M27.45M-127.56M193.71M-67.03M-3.4M25.15M-37.6M-16.34M-20.61M6.16M7.91M-907K16.91M19.92M-52.4M10.57M-6.09M
Capital Expenditures239.94M-65K-165K-426K-113K-277K-283K-334K-567K-350K-126K-240K-28K-204K-642K-1.24M-8.44M-279K-164K-534K
CapEx % of Revenue624.5%------0.3%1.9%0.54%0.3%1.78%5.19%12.75%10.66%27.43%400.86%19.32%14.02%27.77%
Acquisitions00000125.99M03.07K00126K240K28K0033K076K00
Investments--------------------
Other Investing0240M00000-3.07K25.72K-37.25K-126K-240K-28K8.11K-265-33K7.63M-76K00
Cash from Financing-68.06M-42.17M62.88M-106.08M124.25M6.32M174.53M60.7M81.05M75M68.7M86.83M50.86M21.65M32.97M9.49M-2.96M59.52M15.91M2.93M
Debt Issued (Net)-99.15M-89.16M-41.34M-101.58M123.83M-1.82M98.2M-1.14M109.62M-431K24.16M15.33M11.48M0298K8.89M-3.26M-4.12M15.87M-1M
Equity Issued (Net)45.69M46.99M-11.85M-4.65M415K8.38M93.67M54.24M063.66M38.04M79.08M37.75M20.99M32.31M0063.64M40K3.7M
Dividends Paid00000000000000000000
Share Repurchases-5.77M0-11.85M-4.65M000000000003.15M0-48K00
Other Financing-14.61M0116.07M150K0-241K-17.34M7.6M-28.57M11.77M6.5M-7.58M1.62M662K369K595K299K00239K
Net Change in Cash84K6.26M-3.71M-3.9M-89.8M90.31M7.42M-2.78M2.47M1.17M859K1.01M-1.03M-136K-2.48M727K2.46M-11.91M6.8M-17.48M
Free Cash Flow-68.73M-116.16M-148.97M74.3M-86.6M-110M-100.37M-60.41M-104.3M-36.58M-51.63M-65.45M-58.07M-29.9M-35.19M-26.91M-22.94M-19.31M-19.84M-14.85M
FCF Margin %-178.88%-------54.03%-349.22%-56.42%-124.06%-484.48%-10774.03%-1868.69%-584.41%-594.81%-1089.79%-1336.98%-1695.47%-772.13%
FCF Growth %42.2%22.02%-300.5%185.8%21.28%-9.59%-66.15%42.09%-185.16%29.16%21.11%-12.7%-94.23%15.04%-30.79%-17.3%-18.82%2.68%-33.6%-
FCF per Share-0.77-1.83-2.561.18-1.38-1.76-1.76-1.22-2.15-0.80-1.28-1.74-1.75-1.05-1.46-1.21-1.07-2.67-1.85-1.04
FCF Conversion (FCF/Net Income)-0.55x34.65x0.95x-0.63x-1.82x0.98x0.72x0.71x0.82x0.68x0.77x0.87x0.79x0.75x0.90x0.90x0.50x0.90x0.83x0.62x
Interest Paid11.16M35.42M35.69M29.92M0011.6M0000000000000
Taxes Paid-86K153K165K3.29M0000000000000000

Key Metrics

Growth RegimeAccelerating
ProfitabilityStrained
Balance SheetVulnerable
Cash FlowMixed
Top Statement Risk

Critical liquidity and regulatory risk

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Earnings Quality Divergence in Launch Quarter

The Q2 2026 operating cash flow of $4.1 million represents only 31% of the $13.2 million net income, suggesting that a significant portion of the reported profit is non-cash or tied to working capital movements rather than immediate cash generation.

This conversion ratio is a stark reversal from the prior four quarters, where operating cash flow consistently exceeded net income, indicating that the new revenue stream from YARTEMLEA may be subject to different collection dynamics or accrual patterns. The divergence warrants close monitoring, as the sustainability of the cash flow profile depends on the quality of this new commercial revenue, not just its accounting recognition.

FCF Inflection Masked by Historical Burn

Omeros generated positive free cash flow of $4.1 million in Q2 2026, its first positive quarter in over two years, yet this follows a cumulative free cash flow deficit exceeding $250 million over the prior eight quarters.

The positive FCF is a critical milestone, but its magnitude is modest relative to the company's historical cash burn and the $9.66 million cash balance reported. The trajectory is now dependent on the ramp of YARTEMLEA royalties and the management of R&D spend for late-stage programs like narsoplimab and OMS906, making the positive quarter a potential inflection point rather than a confirmed trend.

Working Capital Swings Drive Cash Volatility

Working capital changes have been the primary driver of operating cash flow volatility, with a $3.3 million use of cash in Q2 2026 following a $5.2 million use in Q1, indicating potential challenges in converting new revenue to cash.

The pattern of working capital consuming cash in recent quarters, despite the emergence of revenue, suggests that receivables may be building or that the company is extending terms to support the YARTEMLEA launch. This dynamic is critical to watch, as persistent working capital drag could undermine the cash flow benefits of the new revenue stream and accelerate the need for external financing.

Capital Deployment Shifts to Share Repurchases

In Q2 2026, Omeros deployed $1.6 million for share repurchases, marking a shift from the prior pattern of using cash primarily for operations and minimal capital expenditures.

This repurchase activity, while small in absolute terms, is notable given the company's precarious $9.66 million cash position and history of dilutive financing. It may signal management's confidence in the new revenue trajectory, but it also raises questions about capital allocation priorities when the cash runway is measured in quarters, not years.

Cash Flow Statement Obscures True Burn Rate

The reported $4.1 million operating cash flow in Q2 2026 is likely overstated as a sustainable figure, as it excludes the full cash impact of ongoing R&D for narsoplimab and OMS906, which are capitalized or accrued.

The cash flow statement does not fully capture the future cash obligations tied to the company's clinical pipeline, which represent the core of its operational strategy. Furthermore, the treatment of the Omidria royalty stream and potential milestone payments can create timing differences between cash receipt and revenue recognition, obscuring the true underlying cash generation capability of the business.

OMER — Frequently Asked Questions

Quick answers to the most common questions about buying OMER stock.

How much cash does Omeros Corporation (OMER) generate from operations?

Omeros Corporation (OMER) generated $-116.1M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Omeros Corporation's free cash flow?

Omeros Corporation (OMER) reported negative free cash flow of $116.2M in 2025, indicating capital requirements exceeded cash from operations.

What is Omeros Corporation's capital expenditure (CapEx)?

Omeros Corporation (OMER) spent $0.1M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.